Betulinic Acid Selectively Increases Protein Degradation and Enhances Prostate Cancer-Specific Apoptosis: Possible Role for Inhibition of Deubiquitinase Activity

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Reiner, Teresita ^a   Parrondo, Ricardo ^a   de las Pozas, Alicia ^a   Palenzuela, Deanna ^a   Perez Stable, Carlos ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BETULIC ACID; CYCLIN D1; DEUBIQUITINASE; DOCETAXEL; UBIQUITIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MALE; MITOSIS INHIBITION; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN DEGRADATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; MALE; MICE; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE HYDROLASES; POLYUBIQUITIN; PROSTATIC NEOPLASMS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; TRITERPENES; UBIQUITINATION;

EID: 84873738624     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056234     Document Type: Article

References (48)

1. Luo J, Solimini NL, Elledge SJ, (2009) Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136: 823-837.
2. Glickman MH, Ciechanover A, (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82: 373-428.
3. Orlowski RZ, Kuhn DJ, (2008) Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14: 1649-1657.
4. Morris MJ, Kelly WK, Slovin S, Ryan C, Eicher C, et al. (2007) A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer. J Urol 178: 2378-2383.
5. Fulda S, Kroemer G, (2009) Targeting mitochondrial apoptosis by betulinic acid in human cancers. Drug Disc Today 14: 885-890.
6. Huang L, Ho P, Chen CH, (2007) Activation and inhibition of the proteasome by betulinic acid and its derivatives. FEBS Lett 581: 4955-4959.
7. Katsiki M, Chondrogianni N, Chinou I, Rivett AJ, Gonos ES, (2007) The olive constituent oleuropein exhibits proteasome stimulatory properties in vitro and confers life span extension of human embryonic fibroblasts. Rejuvenation Res 10: 157-172.
8. Chintharlapalli S, Papineni S, Ramaiah SK, Safe S, (2007) Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res 67: 2816-2823.
9. Reyes-Turcu FE, Ventii KH, Wilkinson KD, (2009) Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu Rev Biochem 78: 363-397.
10. Hussain S, Zhang Y, Galardy PJ, (2009) DUBs and cancer: the role of deubiquitinating enzymes as oncogenes, non-oncogenes and tumor suppressors. Cell Cycle 8: 1688-1697.
11. Sacco JJ, Coulson JM, Clague MJ, Urbé S, (2010) Emerging roles of deubiquitinases in cancer-associated pathways. IUBMB Life 62: 140-157.
12. Colland F, (2010) The therapeutic potential of deubiquitinating enzyme inhibitors. Biochem Soc Trans 38 (Pt 1) (): 137-143.
13. Love KR, Catic A, Schlieker C, Ploegh HL, (2007) Mechanisms, biology and inhibitors of deubiquitinating enzymes. Nat Chem Biol 3: 697-705.
14. Colland F, Formstecher E, Jacq X, Reverdy C, Planquette C, et al. (2009) Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol Cancer Ther 8: 2286-2295.
15. Lee BH, Lee MJ, Park S, Oh DC, Elsasser S, et al. (2010) Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 467: 179-184.
16. Kapuria V, Peterson LF, Fang D, Bornmann WG, Talpaz M, et al. (2010) Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res 70: 9265-9276.
17. Liu J, Xia H, Kim M, Xu L, Li Y, et al. (2011) Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell 147: 223-234.
18. D'Arcy P, Brnjic S, Olofsson MH, Fryknäs M, Lindsten K, et al. (2011) Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat Med 17: 1636-1640.
19. Shin YG, Cho KH, Chung SM, Graham J, Das Gupta TK, et al. (1999) Determination of betulinic acid in mouse blood, tumor and tissue homogenates by liquid chromatography-electrospray mass spectrometry. J Chromatogr B Biomed Sci Appl 732: 331-336.
20. Reiner T, de las Pozas A, Gomez LA, Perez-Stable C, (2009) Low dose combination of 2-methoxyestradiol and docetaxel can block prostate cancer cells in mitosis and induce apoptosis. Cancer Lett 276: 21-31.
21. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, et al. (2003) Molecular characterization of human prostate carcinoma cell lines. Prostate 57: 205-225.
22. Gomez LA, de las Pozas A, Perez-Stable C, (2006) Sequential combination of flavopiridol and docetaxel reduces the levels of XIAP and AKT proteins and stimulates apoptosis in human LNCaP prostate cancer cells. Mol Cancer Ther 5: 1216-1226.
23. Gottlieb RA, Granville DJ, (2002) Analyzing mitochondrial changes during apoptosis. Methods 26: 341-347.
24. Krishan A, (1990) Rapid DNA content analysis by the propidium iodide-hypotonic citrate method. Methods Cell Biol 33: 121-125.
25. Perez-Stable C, (2006) 2-Methoxyestradiol and paclitaxel have similar effects on the cell cycle and induction of apoptosis in prostate cancer cells. Cancer Lett 231: 49-64.
26. Newman RM, Mobascher A, Mangold U, Koike C, Diah S, et al. (2004) Antizyme targets cyclin D1 for degradation. A novel mechanism for cell growth repression. J Biol Chem 279: 41504-41511.
27. Kasperczyk H, La Ferla-Bruhl K, Westhoff MA, Behrend L, Zwacka RM, et al. (2005) Betulinic acid as new activator of NF-kappaB: molecular mechanisms and implications for cancer therapy. Oncogene 24: 6945-6956.
28. Parrondo R, de las Pozas A, Reiner T, Rai P, Perez-Stable C, (2010) NF-κB activation enhances cell death by antimitotic drugs in human prostate cancer cells. Mol Cancer 9: 182.
29. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, et al. (1995) Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92: 3439-3443.
30. Kaplan-Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, et al. (2003) Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 55: 219-237.
31. LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, et al. (2008) IAP-targeted therapies for cancer. Oncogene 27: 6252-6275.
32. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, et al. (1999) Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397: 441-446.
33. Borodovsky A, Kessler BM, Casagrande R, Overkleeft HS, Wilkinson KD, et al. (2001) A novel active site-directed probe specific for deubiquitylating enzymes reveals proteasome association of USP14. EMBO J 20: 5187-5196.
34. Pisha E, Chai H, Lee IS, Chagwedera TE, Farnsworth NR, et al. (1995) Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nat Med 1: 1046-1051.
35. Zuco V, Supino R, Righetti SC, Cleris L, Marchesi E, et al. (2002) Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. Cancer Lett 175: 17-25.
36. Kessler JH, Mullauer FB, de Roo GM, Medema JP, (2007) Broad in vitro efficacy of plant-derived betulinic acid against cell lines derived from the most prevalent human cancer types. Cancer Lett 251: 132-145.
37. Gao Y, Jia Z, Kong X, Li Q, Chang DZ, et al. (2011) Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis. Cancer Res 71: 5182-5193.
38. Soldatenkov VA, Dritschilo A, (1997) Apoptosis of Ewing's sarcoma cells is accompanied by accumulation of ubiquitinated proteins. Cancer Res 57: 3881-3885.
39. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, et al. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10: 33-39.
40. Drobnjak M, Osman I, Scher HI, Fazzari M, Cordon-Cardo C, (2000) Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res 6: 1891-1895.
41. Comstock CE, Augello MA, Schiewer MJ, Karch J, Burd CJ, et al. (2011) Cyclin D1 is a selective modifier of androgen-dependent signaling and androgen receptor function. J Biol Chem 286: 8117-8127.
42. Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, et al. (2011) SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 470: 269-273.
43. Song MS, Salmena L, Carracedo A, Egia A, Lo-Coco F, et al. (2008) The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature 455: 813-817.
44. Kon N, Kobayashi Y, Li M, Brooks CL, Ludwig T, et al. (2010) Inactivation of HAUSP in vivo modulates p53 function. Oncogene 29: 1270-1279.
45. Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, et al. (2010) Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 463: 103-107.
46. Dupont S, Mamidi A, Cordenonsi M, Montagner M, Zacchigna L, et al. (2009) FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. Cell 136: 123-135.
47. Faus H, Meyer HA, Huber M, Bahr I, Haendler B, (2005) The ubiquitin-specific protease USP10 modulates androgen receptor function. Mol Cell Endocrinol 245: 138-146.
48. Draker R, Sarcinella E, Cheung P, (2011) USP10 deubiquitylates the histone variant H2A.Z and both are required for androgen receptor-mediated gene activation. Nucleic Acids Res 39: 3529-3542.